Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) was the target of a significant increase in short interest during the month of August. As of August 31st, there was short interest totalling 1,550,000 shares, an increase of 22.0% from the August 15th total of 1,270,000 shares. Currently, 7.8% of the shares of the stock are sold short. Based on an average trading volume of 81,500 shares, the days-to-cover ratio is currently 19.0 days.
Shares of NASDAQ:DAWN traded up $1.46 on Wednesday, reaching $22.01. 82,524 shares of the company traded hands, compared to its average volume of 133,478. The business has a 50-day simple moving average of $24.45. Day One Biopharmaceuticals has a 52 week low of $17.19 and a 52 week high of $28.70.
Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings data on Monday, August 9th. The company reported ($5.04) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($4.72). As a group, research analysts expect that Day One Biopharmaceuticals will post 0.94 EPS for the current fiscal year.
DAWN has been the topic of a number of research analyst reports. Piper Sandler initiated coverage on Day One Biopharmaceuticals in a research note on Monday, June 21st. They issued an “overweight” rating and a $44.00 target price on the stock. JPMorgan Chase & Co. started coverage on Day One Biopharmaceuticals in a research note on Monday, June 21st. They set an “overweight” rating and a $38.00 price objective on the stock. Wedbush started coverage on Day One Biopharmaceuticals in a research note on Monday, June 21st. They set an “outperform” rating and a $30.00 price objective on the stock. Finally, Cowen started coverage on Day One Biopharmaceuticals in a research note on Monday, June 21st. They set an “outperform” rating on the stock.
About Day One Biopharmaceuticals
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.
Featured Story: Understanding dividend yield and dividend payout ratio
Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.